Abiopharma

Poseida Therapeutics (PSTX) Announces Clinical Trial Update Poseida Therapeutics (PSTX) provided an update on its clinical development programs. Clinical Development Highlights:

• Update Type: Trial Timeline Adjustment
• Primary Factors: Pandemic-Related Challenges, Regulatory Process
• Collaboration: Common Stock
  • targeting prostate-specific membrane antigen (“PSMA”) being developed to treat patients with metastatic castrate-resistant prostate cancer and salivary gland carcinoma. We are currently evaluating P-PSMA-101 in a Phase 1 clinical trial. We presented encouraging preliminary results from our Phase 1 clinical trial of P-PSMA-101 in our first solid tumor indication on February 17, 2022
  • targeting PSMA utilizing a VH binder, in preclinical development. • P-BCMA-ALLO1, which is a fully allogeneic CAR-T product candidate targeting BCMA, being developed to treat relapsed/refractory multiple myeloma patients. We are currently evaluating P-BCMA-ALLO1 in a Phase 1 clinical trial and we expect initial clinical data from our Phase 1 clinical trial in the second half of 2022
  • anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the fact that the Roche Collaboration Agreement may not become effective based on Hart-Scott-Rodino Antitrust Improvements Act of 1976